|THURSDAY, OCTOBER 18
FORUM 2: CANCER PREVENTION: LESSONS LEARNED AND PROSPECTS FOR FUTURE DRUG DEVELOPMENT
Session Co-Chairpersons: Victoria M. Richon, Epizyme, Inc,. Cambridge, MA, and Jaye L. Viner, Millennium Pharmaceuticals, Cambridge, MA
7:00 a.m.-8:00 a.m.
Lessons learned from 20 years of chemoprevention research
Victor G. Vogel, Geisinger Health Systems, Danville, PA
What are the hurdles for moving approved drugs into the prevention setting?
Pamela M. Munster, University of California, San Francisco, CA
Discussion / Q&A
PLENARY SESSION 3: OBESITY, DIABETES, AND METABOLIC SYNDROME
Session Chairperson: Reuben J. Shaw, Salk Institute for Biomedical Studies, La Jolla, CA
8:00 a.m.-10:00 a.m.
The nutrient-sensing mTOR pathway in cancer initiation and progression
Brendan Manning, Harvard School of Public Health, Boston, MA
Regulation of tumor metabolism by sirtuins
Marcia C. Haigis, Harvard Medical School, Boston, MA
The LKB1-AMPK pathway coordinates metabolic reprogramming with growth control
Reuben J. Shaw
Role of autophagy in cancer
Eileen P. White, UMDNJ-The Cancer Institute of New Jersey, New Brunswick, NJ
CONCURRENT SESSIONS 3-4
10:15 a.m.-12:00 p.m.
CONCURRENT SESSION 3: CURRENT CONTROVERSIES IN CANCER SCREENING
Session Chairperson: Electra D. Paskett, The Ohio State University Comprehensive Cancer Center, Columbus, OH
Electra D. Paskett
Predictors of change in colorectal cancer screening decision stage among participants in a randomized, controlled trial of genetic and environmental risk assessment
Ronald E. Myers, Thomas Jefferson University, Philadelphia, PA
Is newer better? Use of technology to encourage cancer screening among various populations
Celette Skinner, UT Southwestern Medical Center, Dallas, TX
Cost effectiveness of lung cancer screening
James L. Mulshine, Rush Medical College, Rush University, Chicago, IL
The effect of the new screening guidelines on uptake of screening tests
Steve Taplin, National Cancer Institute, Rockville, MD
CONCURRENT SESSION 4: NSAIDS AND BEYOND
Session Chairperson: Ernest T. Hawk, The University of Texas MD Anderson Cancer Center, Houston, TX
Aspirin for cancer prevention: Are we ready?
Andrew T. Chan, Massachusetts General Hospital, Boston, MA
A novel approach to biomolecular imaging of COX-2
Jashim Uddin, Vanderbilt University School of Medicine, Nashville, TN
Development of NSAID eflornithine combinations for treating cancer risk factors
Eugene W. Gerner, University of Arizona Cancer Center, Oro Valley, AZ
Aspirin mediated down-regulation of Warburg Kinase AKT1 in patients with Barrett's Esophagus: Implications in neoplastic transformation *
Cathrine J. DeMars, Mayo Clinic, Rochester, MN
POSTER SESSION B / LUNCH
12:00 p.m.-2:30 p.m.
- Behavioral and Social Science
- Biomarkers and Early Detection Research
- Cell, Molecular, and Tumor Biology
- Chemoprevention and Biological Therapies
- Clinical Prevention Trials (by Organ Site)
- Epidemiology / Lifestyle Factors
- Preclinical and Translational Prevention Studies (by Organ Site)
CONCURRENT SESSIONS 5-6
2:30 p.m.-4:15 p.m.
CONCURRENT SESSION 5: GLOBAL CHALLENGES: ENVIRONMENTAL CHANGES
Session Chairperson: Thomas W. Kensler, University of Pittsburgh, Pittsburgh, PA
Viral and dietary factors in declining liver cancer mortality in Qidong, China
Thomas W. Kensler
Maria Argos, University of Chicago, Chicago, IL
Lifestyle, infection, and genetic factors in relation to biliary tract cancer
Ann W. Hsing, Cancer Prevention Institute of California, Fremont, CA
Curcumin is an effective chemopreventive substance for betel quid chewer’s oral precancer in Sri Lanka*
Itsuo Chiba, Health Sciences University of Hokkaido, Sapporo, Japan
CONCURRENT SESSION 6: RECENT RESULTS ON MECHANISMS AND PREVENTION OF TOBACCO-INDUCED CANCER
Session Chairperson: Stephen S. Hecht, University of Minnesota Masonic Cancer Center, Minneapolis, MN
Induction of oral cavity cancer in rats by (S)-N'-Nitrosonornicotine, a constituent of smokeless tobacco
Stephen S. Hecht
Epigenetic deregulation of microRNAs during tobacco carcinogen-induced transformation of bronchial epithelial cells
Steven A. Belinsky, Lovelace Respiratory Research Institute, Albuquerque NM
Translating airway gene-expression into biomarkers of smoking and lung cancer
Avrum E. Spira, Boston University, Boston, MA
Exposure to tobacco smoke from husband and breast cancer risk in Japanese women *
Keiko Wada, Gifu University Graduate School of Medicine, Gifu, Japan
PLENARY SESSION 4: GENOMICS AND PREVENTION: WILL GENOMICS LEAD TO OPTIMIZED CANCER PREVENTION?
Session Chairperson: Timothy R. Rebbeck, University of Pennsylvania School of Medicine, Phildelphia, PA
4:15 p.m.-6:15 p.m.
The promise of GWAS studies to assess cancer prevention
Stephen J. Chanock, National Cancer Institute, Bethesda, MD
Insights on cancer risk from normal breast tissue gene expression
Melissa Troester, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
SERM breast cancer prevention pharmacogenomics: Beyond biomarkers
Richard M. Weinshilboum, Mayo Clinic College of Medicine, Rochester, MN
How will genomic information be useful to limit cancer risk behaviors?
Christopher I. Amos, Geisel School of Medicine, Dartmouth College, Lebanon, NH
BEHAVIORAL SCIENCE IN CANCER RESEARCH WORKING GROUP NETWORKING EVENT
6:30 p.m.-8:00 p.m.
MOLECULAR EPIDEMIOLOGY WORKING GROUP TOWN MEETING AND RECEPTION
Chairperson: James R. Cerhan, Mayo Clinic College of Medicine, Rochester, MN
6:30 p.m.-8:00 p.m.
Involvement in consortia and major projects, particularly for junior professionals
Stephen J. Chanock, director, Cancer Genomics Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD
Funding opportunities for new and early-stage investigators
Deborah M. Winn, deputy director, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD